Puravankara Ltd
PURVAPuravankara Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the P/E sits at the 75th percentile of its own range — the multiple has already done part of the work.
The price is in a downtrend (79 weeks in) while the P/E sits at the 75th percentile of its own 11-year range. Underneath, the last four quarters read improving, and 835% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Puravankara Ltd trades at ₹211, in a downtrend and 79 weeks into that stage. That is −8.0% against its own 200-day average. It sits at 33% of a 52-week range of ₹173 to ₹289. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is in a downtrend — week 79 of stage 4, confirmed. At ₹211 it trades −8.0% versus its 200-day average and sits at 33% of its 52-week range (₹173–₹289).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +312% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-07-10) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Puravankara Ltd trades at 78.5× P/E, at the pricey end of its own range (75th percentile). Its long-run median P/E is 18.0×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 78.5× is at the pricey end of its own range (75th percentile), against a long-run median of 18.0× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
The price move, decomposed: over 5y, of the +13.9%/yr price move, ~−17.6%/yr came from earnings growth and ~+31.5 pp from the multiple (expanding); over 10y, of the +15.9%/yr price move, ~−3.6%/yr came from earnings growth and ~+19.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources disagree by up to 335% on reported income across 15 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Puravankara Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 8 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +85.7% | +44.6% | +31.2% | +9.0% |
| Profit | — | −5.2% | — | −3.7% |
| EPS | — | −1.3% | — | −2.6% |
| Share price | −26.4% | +26.7% | +13.9% | +15.9% |
4-Factor Sector Score
50.6/100 — rank 10 of 26 in Realty - Construction & Contracting · 58% evidence confidence
Puravankara Ltd scores 50.6 out of 100 against the 26 companies it is compared with in Realty - Construction & Contracting, ranking 10. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 24 + 11.2 + 9.1 + 6.3 = 50.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Puravankara Ltd reported ₹1,502 Cr of revenue in the Mar 26 quarter, +177.1% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 9.0% a year. The last full year, FY26, came in at ₹3,740 Cr. The last four reported quarters add to ₹3,739 Cr.
FY26 revenue came in at ₹3,740 Cr (+85.7% on the year), capping 10 years at 9.0% compound. The latest quarter (Mar 26) printed ₹1,502 Cr, +177.1% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +105.7% growth against the decade's 9.0% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +85.7% over the last 4 quarters against +30.8%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Puravankara Ltd's operating margin is 20.0% in the Mar 26 quarter, +14.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 14.0% to 36.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 20.0%, +14.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 14.0%–36.0%.
Why the margin moved: operating margin went +14.4 pp year on year while gross margin went −47.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Puravankara Ltd earned ₹110 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹57.0 Cr. The 10-year compound rate is −3.7%. That is 7.3% of the quarter's revenue. The same quarter a year earlier lost ₹88.0 Cr. 8 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹110 Cr, null year on year. On the full year, FY26 printed ₹57.0 Cr (null), and the 10-year compound rate is −3.7%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 835% of Puravankara Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹345 Cr of operating cash against ₹57.0 Cr of profit. After ₹913 Cr of capital spending, ₹−568 Cr was left as free cash.
FY26: operating cash of ₹345 Cr against reported profit of ₹57.0 Cr, leaving free cash of ₹−568 Cr after ₹913 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 835% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 835%: the cash cycle tightened 39 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 10.5× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Puravankara Ltd's cash conversion cycle runs 77 days in FY26, down from 116 days in FY21. Capital spending ran ₹1,100 Cr over the last 3 years. At FY26 sales of ₹3,740 Cr each day of that cycle holds about ₹10.2 Cr, so roughly ₹789 Cr sits inside the business at any moment.
FY26: debtors at 77 days (an asset-light business — no inventory to speak of) — for a full cycle of 77 days, tighter than FY21's 116.
In money terms: at FY26 sales of ₹3,740 Cr, each day of the cycle holds about ₹10.2 Cr — so the 77-day loop keeps roughly ₹789 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,100 Cr over the last 3 fiscal years against ₹105 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹1.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Puravankara Ltd earns a ROCE of 11% in FY26. That is up from a trough of 6% in FY25. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 1.5% net margin on 0.22× asset turns.
FY26 ROCE is 11%, recovered from a FY25 trough of 6% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 1.5% net margin × 0.22× asset turns × 9.65× balance-sheet leverage ≈ 3.2% on equity. Margin does its share; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 335% on reported income across 15 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Puravankara Ltd carries ₹5,595 Cr of borrowings against ₹1,788 Cr of equity in FY26, a debt-to-equity of 3.13. Operating profit covers the interest bill 1×. Over 5 years borrowings went from ₹2,835 Cr to ₹5,595 Cr. Capital spending ran ₹1,100 Cr across the last 3 of those years.
FY26: borrowings of ₹5,595 Cr against equity of ₹1,788 Cr — a debt-to-equity of 3.13. Operating profit covers the interest bill 1×. Over 5 years borrowings went from ₹2,835 Cr to ₹5,595 Cr while capital spending ran ₹1,100 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 335% on reported income across 15 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Puravankara Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved −0.4 points over the same window, to 0.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −0.4 points over 8 quarters to 16.6%; Domestic institutions: −0.4 points over 8 quarters to 0.6%; Promoters: +0.0 points over 8 quarters to 75.0%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Puravankara Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Ashiana Housing LtdASHIANA | 64.2/100Mixed-positive evidence96% evidence | LEADER | 26.4/35 Revenue 100% · PAT 100% · OPM change -2 pp 88% evidence | 13.4/25 ROCE 14.4% · OPM 6% 100% evidence | 5.5/20 P/E 33.3× · PEG 4.68 100% evidence | 18.9/20 RS sector 20.7% · RS bench 19.2% · 1Y 23.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 13.4 + 5.5 + 18.9 = 64.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Arihant Foundations & Housing LtdARIHANT | 62.8/100Mixed-positive evidence77% evidence | TURNING | 18.8/35 Revenue 100% · PAT 41.9% · OPM change -17.1 pp 83% evidence | 17.4/25 ROCE 17.5% · OPM 7.5% 95% evidence | 10.7/20 P/E 19.3× · PEG — 50% evidence | 15.9/20 RS sector 10.4% · RS bench 6.5% · 1Y -1.6%2 of 10 weeks ahead 70% evidence |
| Exact sum: 18.8 + 17.4 + 10.7 + 15.9 = 62.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3AGI Infra LtdAGIIL | 61.8/100Mixed-positive evidence89% evidence | FADING | 20.2/35 Revenue 8.6% · PAT 43.9% · OPM change 5 pp 88% evidence | 19.9/25 ROCE 20.1% · OPM 24% 100% evidence | 10.8/20 P/E 41.1× · PEG 1.37 65% evidence | 10.9/20 RS sector 4.1% · RS bench 3% · 1Y 46.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 19.9 + 10.8 + 10.9 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Kesar India Ltd543542 | 61.2/100Mixed-positive evidence67% evidence | TURNING | 18.4/35 Revenue 91.9% · PAT 12.6% · OPM change 16 pp 71% evidence | 19.8/25 ROCE 23.4% · OPM 24% 76% evidence | 8.8/20 P/E 133× · PEG — 15% evidence | 14.2/20 RS sector 20% · RS bench 19.4% · 1Y 81.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 19.8 + 8.8 + 14.2 = 61.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shriram Properties LtdSHRIRAMPPS | 56.6/100Mixed-positive evidence83% evidence | ASLEEP | 23.4/35 Revenue 53.8% · PAT 32.5% · OPM change -1 pp 83% evidence | 9.9/25 ROCE 8% · OPM 11% 95% evidence | 12.9/20 P/E 14.2× · PEG — 50% evidence | 10.4/20 RS sector -0.7% · RS bench -2.2% · 1Y -12.1%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23.4 + 9.9 + 12.9 + 10.4 = 56.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Capacite Infraprojects LtdCAPACITE | 56.0/100Mixed-positive evidence77% evidence | ASLEEP | 18.0/35 Revenue 11.6% · PAT -4.9% · OPM change 2 pp 83% evidence | 17.3/25 ROCE 15.5% · OPM 15% 95% evidence | 13.8/20 P/E 9.6× · PEG — 50% evidence | 6.9/20 RS sector -7.6% · RS bench -16.3% · 1Y -32.6%2 of 10 weeks ahead 70% evidence |
| Exact sum: 18 + 17.3 + 13.8 + 6.9 = 56 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Geecee Ventures LtdGEECEE | 53.7/100Mixed-positive evidence83% evidence | BREAKING OUT | 14.8/35 Revenue -44.4% · PAT -12.5% · OPM change 59 pp 83% evidence | 10.7/25 ROCE 6.3% · OPM 87% 95% evidence | 9.8/20 P/E 17.5× · PEG — 50% evidence | 18.4/20 RS sector 7.8% · RS bench 6.1% · 1Y -5.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 10.7 + 9.8 + 18.4 = 53.7 · Decision use: Price leads the evidence: RS versus the benchmark is 6.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 8Hubtown LtdHUBTOWN | 52.4/100Mixed-positive evidence73% evidence | ASLEEP | 25.3/35 Revenue 57.8% · PAT 100% · OPM change 40 pp 88% evidence | 10.8/25 ROCE 9.5% · OPM 49% 100% evidence | 10.5/20 P/E 18.2× · PEG — 15% evidence | 5.8/20 RS sector -10.6% · RS bench -24.3% · 1Y -39.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 25.3 + 10.8 + 10.5 + 5.8 = 52.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.6% and the one-year return is -39.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 9Sunteck Realty LtdSUNTECK | 50.8/100Mixed-positive evidence93% evidence | ASLEEP | 25.7/35 Revenue 55.5% · PAT 31.1% · OPM change 10 pp 100% evidence | 8.4/25 ROCE 7.5% · OPM 35% 100% evidence | 13.9/20 P/E 20.8× · PEG 0.87 65% evidence | 2.8/20 RS sector -19% · RS bench -20.2% · 1Y -28%0 of 12 weeks ahead 100% evidence |
| Exact sum: 25.7 + 8.4 + 13.9 + 2.8 = 50.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -19% and the one-year return is -28%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 10Puravankara Ltdthis pagePURVA | 50.6/100Thin evidence · provisional58% evidence | ASLEEP | 24.0/35 Revenue 85.7% · PAT 100% · OPM change 14 pp 62% evidence | 11.2/25 ROCE 11.2% · OPM 20% 76% evidence | 9.1/20 P/E 78.5× · PEG — 15% evidence | 6.3/20 RS sector -13.6% · RS bench -11.5% · 1Y -23.2%5 of 10 weeks ahead 70% evidence |
| Exact sum: 24 + 11.2 + 9.1 + 6.3 = 50.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Ajmera Realty & Infra India LtdAJMERA | 50.5/100Mixed-positive evidence72% evidence | TURNING | 20.5/35 Revenue 47.7% · PAT 24.6% · OPM change -4 pp 83% evidence | 16.3/25 ROCE 14.3% · OPM 25% 76% evidence | 10.1/20 P/E 16.6× · PEG — 50% evidence | 3.6/20 RS sector -24.9% · RS bench -21.2% · 1Y -32.6%3 of 11 weeks ahead 70% evidence |
| Exact sum: 20.5 + 16.3 + 10.1 + 3.6 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Suratwwala Business Group LtdSBGLP | 50.5/100Thin evidence · provisional56% evidence | 18.3/35 Revenue 100% · PAT 100% · OPM change 45 pp 40% evidence | 12.3/25 ROCE 12.4% · OPM 37% 71% evidence | 14.3/20 P/E 16.8× · PEG — 50% evidence | 5.6/20 RS sector -15.1% · RS bench -14.8% · 1Y -31.9%2 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 18.3 + 12.3 + 14.3 + 5.6 = 50.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Eldeco Housing & Industries LtdELDEHSG | 50.2/100Mixed-positive evidence77% evidence | ASLEEP | 18.2/35 Revenue 23.1% · PAT 12.9% · OPM change -4.7 pp 83% evidence | 11.8/25 ROCE 7.7% · OPM 10.9% 95% evidence | 6.5/20 P/E 31.3× · PEG — 50% evidence | 13.7/20 RS sector 28.2% · RS bench -9.7% · 1Y 1.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 18.2 + 11.8 + 6.5 + 13.7 = 50.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Suraj Estate Developers LtdSURAJEST | 49.6/100Mixed-negative evidence83% evidence | ASLEEP | 15.7/35 Revenue 1.3% · PAT -10% · OPM change 28 pp 83% evidence | 17.2/25 ROCE 14.5% · OPM 50% 95% evidence | 14.1/20 P/E 10.4× · PEG — 50% evidence | 2.6/20 RS sector -18.5% · RS bench -19.8% · 1Y -38.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 17.2 + 14.1 + 2.6 = 49.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 15Raymond LtdRAYMOND | 49.0/100Mixed-negative evidence65% evidence | TURNING | 19.1/35 Revenue 13.6% · PAT -29.8% · OPM change 4 pp 83% evidence | 9.5/25 ROCE 3.1% · OPM 12% 76% evidence | 11.5/20 P/E 0.7× · PEG — 15% evidence | 8.9/20 RS sector -18.2% · RS bench 14% · 1Y -17.5%10 of 10 weeks ahead 70% evidence |
| Exact sum: 19.1 + 9.5 + 11.5 + 8.9 = 49 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Arvind SmartSpaces LtdARVSMART | 48.5/100Mixed-negative evidence78% evidence | ASLEEP | 13.3/35 Revenue -20.9% · PAT -14.2% · OPM change 17 pp 83% evidence | 15.8/25 ROCE 12.9% · OPM 38% 76% evidence | 9.1/20 P/E 28.2× · PEG — 50% evidence | 10.3/20 RS sector -0.2% · RS bench -1.6% · 1Y -5.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 15.8 + 9.1 + 10.3 = 48.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Hemisphere Properties India LtdHEMIPROP | 42.0/100Mixed-negative evidence62% evidence | TURNING | 18.9/35 Revenue 9.9% · PAT -49.2% · OPM change 408.3 pp 65% evidence | 0.5/25 ROCE -1.1% · OPM -900% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.6/20 RS sector 6.5% · RS bench -5.8% · 1Y 1.8%2 of 10 weeks ahead 70% evidence |
| Exact sum: 18.9 + 0.5 + 10 + 12.6 = 42 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18PVP Ventures LtdPVP | 40.8/100Mixed-negative evidence65% evidence | FADING | 20.1/35 Revenue 100% · PAT -16.2% · OPM change -10 pp 62% evidence | 6.0/25 ROCE 6.2% · OPM 17.4% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.7/20 RS sector -9.5% · RS bench -10.6% · 1Y 27%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 6 + 10 + 4.7 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Ganesh Housing LtdGANESHHOU | 40.6/100Mixed-negative evidence94% evidence | TURNING | 4.2/35 Revenue -28.6% · PAT -54.1% · OPM change -46 pp 100% evidence | 18.0/25 ROCE 18.8% · OPM 39% 100% evidence | 12.8/20 P/E 23.3× · PEG 0.31 100% evidence | 5.6/20 RS sector -19.7% · RS bench -4.1% · 1Y -16.6%8 of 10 weeks ahead 70% evidence |
| Exact sum: 4.2 + 18 + 12.8 + 5.6 = 40.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Valor Estate LtdDBREALTY | 38.8/100Mixed-negative evidence81% evidence | BREAKING OUT | 19.0/35 Revenue 81.6% · PAT 100% · OPM change -86.8 pp 65% evidence | 6.1/25 ROCE 1.6% · OPM -91% 100% evidence | 4.4/20 P/E 237.7× · PEG 4.19 65% evidence | 9.3/20 RS sector -11.1% · RS bench -12.9% · 1Y -38.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 6.1 + 4.4 + 9.3 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Omaxe LtdOMAXE | 34.8/100Thin evidence · provisional59% evidence | TURNING | 8.6/35 Revenue -19.7% · PAT -1.6% · OPM change -38 pp 62% evidence | 1.9/25 ROCE -110% · OPM -58% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.3/20 RS sector 4% · RS bench 6.5% · 1Y -8.5%1 of 10 weeks ahead 70% evidence |
| Exact sum: 8.6 + 1.9 + 10 + 14.3 = 34.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Keystone Realtors LtdRUSTOMJEE | 33.9/100Adverse evidence72% evidence | TURNING | 12.8/35 Revenue 31.4% · PAT -49.7% · OPM change -3 pp 83% evidence | 8.6/25 ROCE 4.7% · OPM 5% 76% evidence | 6.6/20 P/E 64× · PEG — 50% evidence | 5.9/20 RS sector -11.6% · RS bench -18.8% · 1Y -36%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.8 + 8.6 + 6.6 + 5.9 = 33.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Peninsula Land LtdPENINLAND | 33.8/100Adverse evidence65% evidence | BASING | 13.0/35 Revenue -44.4% · PAT -80% · OPM change -12.7 pp 62% evidence | 6.7/25 ROCE 5.3% · OPM -15% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -34.4% · RS bench -35.9% · 1Y -59.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 6.7 + 10 + 4.1 = 33.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24SignatureGlobal India LtdSIGNATURE | 32.5/100Adverse evidence86% evidence | ASLEEP | 15.8/35 Revenue 3.9% · PAT 100% · OPM change -3 pp 83% evidence | 4.4/25 ROCE 2.6% · OPM 5% 95% evidence | 5.1/20 P/E 322× · PEG 3.94 65% evidence | 7.2/20 RS sector -14.1% · RS bench -15.3% · 1Y -30.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 4.4 + 5.1 + 7.2 = 32.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Kolte Patil Developers LtdKOLTEPATIL | 30.0/100Adverse evidence70% evidence | ASLEEP | 3.4/35 Revenue -57.2% · PAT -80% · OPM change -17.4 pp 88% evidence | 5.2/25 ROCE -0.3% · OPM -2.4% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.4/20 RS sector 1.1% · RS bench -1.8% · 1Y -13.5%3 of 10 weeks ahead 70% evidence |
| Exact sum: 3.4 + 5.2 + 10 + 11.4 = 30 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Laxmi Goldorna House LtdLGHL | 52.3/100Thin evidence · provisional48% evidence | ASLEEP | 16.3/35 Revenue — · PAT — · OPM change -1.5 pp 19% evidence | 16.3/25 ROCE 17% · OPM 18.2% 95% evidence | 9.0/20 P/E 87.5× · PEG — 15% evidence | 10.7/20 RS sector 4.8% · RS bench -26.9% · 1Y -38.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.3 + 16.3 + 9 + 10.7 = 52.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Puravankara Ltd's share price today?
Puravankara Ltd trades at ₹211, −26.4% over the past year. The company is valued at ₹4,999 Cr. The stock sits at 33% of its 52-week range of ₹173–₹289, −8.0% versus its 200-day average. On the tape, the price is in a downtrend, 79 weeks in. — as of 31 July 2026.
What were Puravankara Ltd's latest quarterly results?
Puravankara Ltd reported revenue of ₹1,502 Cr and net profit of ₹110 Cr for the Mar 26 quarter. Earnings per share were ₹4.78. The operating margin was 20.0%, 14.0 pp higher than a year earlier. — as of 31 July 2026.
What is Puravankara Ltd's revenue?
Puravankara Ltd reported revenue of ₹1,502 Cr in the Mar 26 quarter, +177.1% year on year. For the full FY26 fiscal year, revenue was ₹3,740 Cr (+85.7%). Over the last 10 years revenue compounded at 9.0% a year. — as of 31 July 2026.
What is Puravankara Ltd's profit?
Puravankara Ltd earned ₹110 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹57.0 Cr. The operating margin ran 20.0% in the latest quarter. — as of 31 July 2026.
What is Puravankara Ltd's market cap?
Puravankara Ltd's market capitalisation is ₹4,999 Cr at a share price of ₹211. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Puravankara Ltd's P/E ratio?
Puravankara Ltd trades at a P/E of 78.5×, at the 75th percentile of its own 11-year range, against a long-run median of 18.0×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Puravankara Ltd pay a dividend?
Not in its latest year — Puravankara Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 9 of its last 13 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Puravankara Ltd overvalued?
On its own history, Puravankara Ltd looks expensive against its own history: its P/E of 78.5× sits at the 75th percentile of its 11-year range (long-run median 18.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
How is Puravankara Ltd performing?
Puravankara Ltd is in a downtrend, 79 weeks in. Against the NIFTY 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is Puravankara Ltd in an uptrend?
No — the price is in a downtrend (week 79 of stage 4), trading −8.0% versus its 200-day average and at 33% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Puravankara Ltd beating the market?
Not lately — on a trailing-13-week view Puravankara Ltd is currently behind the NIFTY 500 (3 weeks and counting; last ahead the week of 2026-07-10), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +312% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.
Will Puravankara Ltd's share price go up?
This page publishes no price forecast for Puravankara Ltd. What it measures instead: the share price is ₹211, the price is in a downtrend 79 weeks in. Its P/E of 78.5× sits at the 75th percentile of its own 11-year range. Direction is not something this site claims to know. — as of 31 July 2026.
Who owns Puravankara Ltd?
Promoters hold 75.0% of Puravankara Ltd, foreign institutions 16.6%, domestic institutions 0.6% and the public 7.8% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Puravankara Ltd have too much debt?
It carries real leverage — Puravankara Ltd's debt-to-equity is 3.13, and operating profit covers the interest bill 1×. FY26 borrowings were ₹5,595 Cr against equity of ₹1,788 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Puravankara Ltd's capex?
Puravankara Ltd spent ₹1,100 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹913 Cr, with ₹1.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Puravankara Ltd's cash flow?
Puravankara Ltd generated ₹345 Cr of operating cash flow in FY26 and ₹−568 Cr of free cash flow after ₹913 Cr of capital spending. Reported profit that year was ₹57.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Puravankara Ltd's profit real cash?
Yes — over the last 3 fiscal years, 835% of Puravankara Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹345 Cr against reported profit of ₹57.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Puravankara Ltd in its business cycle?
Puravankara Ltd's FY26 operating margin was 18.0%, against a 13-year band of 14.0%–36.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 20.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Puravankara Ltd story?
Biggest watch item: the P/E sits at the 75th percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Puravankara Ltd a stock worth studying right now?
This is not investment advice. The machine read: Puravankara Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.